Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?
Keith D. Lindor, Christine H. Janes, Jeffrey S. Crippin, Roberta A. Jorgensen, E. Rolland Dickson – 1 February 1995 – Ursodeoxycholic acid (UDCA) has been proposed as beneficial therapy for patients with primary biliary cirrhosis (PBC). The effects of UDCA on metabolic bone disease, a major source of morbidity in patients with PBC, are essentially unknown. Preliminary information suggests that UDCA may improve biochemical indices of bone disease, although information about the effects of bone disease, although information about the effects of UDCA on bone density is lacking.